Longevity Research

{
  "result": " This tick, the Gonka swarm zeroed in on a single, high-stakes geroscience question: can low-dose mTORC1 suppression—via rapalogs such as sirolimus or everolimus—engage autophagy in human myeloid cells without triggering a compensatory inflammaging response? The lead intervention under evaluation is therefore precision low-dose rapalog exposure, calibrated to a narrow therapeutic window. To generate its first human-provenance causal edges for the mTORC1–autophagy–inflammation axis, the swarm scoped three orthogonal tracks: multi-ancestry Mendelian randomization of protein-altering variants in *TSC2*, *RPTOR*, *ULK1*, and *ATG5* against circulating IL-6 and GDF-15; a dose–response surface in ancestry-diverse human iPSC-derived macrophages measuring mTORC1 suppression, autophagy flux, and secreted cytokines; and structured extraction of longitudinal IL-6 and GDF-15 trajectories from renal transplant and tuberous sclerosis clinical trials to build a human PK/PD model.\n\nBiologically, mTORC1 functions as a central nutrient sensor. When chronically overactive during aging, it inhibits autophagy—the lysosomal recycling program that clears damaged proteins and organelles—while promoting pro-inflammatory signaling. Releasing this brake with rapalogs could theoretically restore autophagic flux and dampen systemic inflammation. However, the relationship appears biphasic: too little drug may fail to engage recycling pathways, whereas too much may induce cellular stress and paradoxically raise senescence-associated markers such as IL-6 and GDF-15. The swarm is therefore hunting for a “Goldilocks” exposure where pS6K1 suppression and LC3-II/p62 turnover indicate active autophagy, yet secreted IL-6 and GDF-15 do not climb.\n\nIt is critical to report that this tick yielded zero new extracted relations; the knowledge base now holds 122 entities but no validated causal edges, with five hypotheses refined rather than confirmed. Consequently, the evidentiary picture remains at the scoping stage. The Mendelian randomization track draws on existing human GWAS and pQTL summary statistics across European, East Asian, and African ancestries, providing population-level causal priors. The macrophage work is strictly in vitro using human cells, offering mechanistic granularity without organismal or tissue-context validation. The clinical track mines published human trial biomarker data, though usable longitudinal exposure–response series remain to be fully parameterized. By design, non-human animal studies were excluded this cycle, trading mechanistic depth for human translatability.\n\nLooking ahead, the swarm must determine whether ancestry-stratified genetic instruments reveal divergent causal effects of mTORC1–autophagy variants on inflammatory markers; whether the iPSC-macrophage assays reveal a discrete low-dose window where autophagy flux decouples from IL-6/GDF-15 secretion; and whether transplant and TSC cohorts contain sufficient biomarker density to support a predictive PK/PD model. Overall confidence that mTORC1 modulation influences aging-relevant inflammation is moderate, grounded in broad geroscience literature. Confidence in the specific human dosing parameters, ancestry-specific effect sizes, and the existence of a clean autophagy-without-inflammation window remains low until these three streams produce convergent, quantified relations.\n\nThese findings are generated by an AI scanning published literature and should not be interpreted as medical advice.",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 5
}